ArticleBMC endocrine disorders2025
Management for prolactinomas of postmenopausal female patients: a retrospective single-center study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Associations Between Peripheral Blood Inflammatory and Immune Markers and Osteoporotic and Fragility Fractures: A Systematic Review and Meta-Analysis.Calcified tissue international · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo evaluate outcomes of prolactinoma management in postmenopausal women, focusing on treatment withdrawal strategies in premenopausal-diagnosed patients and treatment response in postmenopausal-diagnosed patients.
methodsThis retrospective study analyzed postmenopausal patients with prolactinomas treated at Peking Union Medical College Hospital from 2014 to 2024. Patients were stratified by diagnosis timing (premenopausal vs. postmenopausal), with premenopausal-diagnosed cases further divided by treatment status.
resultsAmong premenopausal-diagnosed patients (n = 53), 35 attempted to discontinue the medication, and 16 of them experienced recurrence, with median time to recurrence of six months (IQR 4.25–9.75). All recurrent cases regained remission upon retreatment. History of unguided withdrawal attempts before menopause were identified in over half (n = 9, 56.25%) of recurrent cases. Subsequent prolactin measurement revealed statistically higher in the recurrence group than in the remission group in last follow-up before withdrawal, 1–6 months (p = 0.000136) and 6–12 months (p = 0.006717) after withdrawal. The postmenopausal-diagnosed subgroup (n = 6) consisted primarily of microadenomas (n = 5) and most showed excellent dopamine agonist response.
conclusionsThis study represents the largest retrospective analysis to date to explore the management of prolactinoma in postmenopausal women. The current evidence indicates that dopamine agonist withdrawal represents a promising therapeutic strategy for postmenopausal patients, and further research is warranted to confirm. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.